For decades, linear TV was the default home for pharma ad budgets. It offered sight, sound, and motion at national scale, which made it the go-to channel for launches and broad awareness. But the audience has moved. In May 2026, streaming accounted for 48.6% of all U.S. TV viewing, while broadcast and cable combined fell to 39.6%.
Budgets are following viewers. eMarketer projects that linear TV’s share of healthcare and pharma ad spending will fall from more than 30% in 2021 to just 12% by 2027, and 2026 is the first year U.S. CTV upfront ad spending is expected to surpass primetime linear TV.
For healthcare marketers weighing CTV vs linear TV advertising, the useful question is what each channel can do for a brand. Below, we compare linear TV vs connected TV across targeting, measurement, cost, and compliance, then walk through why more pharma brands are moving dollars to connected TV (CTV).
Linear TV vs CTV Advertising: Key Differences
The core difference between connected TV vs linear TV is how ads are bought. Linear TV is purchased by network, program, and daypart. Advertisers choose time slots based on panel-measured demographics and accept that most viewers won’t be in their target audience. CTV runs on internet-connected devices such as smart TVs, streaming sticks, and game consoles, and is usually bought programmatically. That lets advertisers decide who sees an ad at the household level instead of inferring it from what’s on air.
For healthcare brands, that gap matters more than in most categories. A brand treating a condition that affects 1% of adults pays to reach the other 99% on linear. On CTV, the same brand can build an audience from de-identified health data, cap how often each household sees the ad, and tie exposure to prescriptions. Linear still has strengths, especially simultaneous live reach during sports and tentpole events. Below, you'll find a CTV-vs.-linear-TV advertising targeting comparison, along with the other factors healthcare marketers weigh when planning.
Targeting approach
Linear: Bought by network, program, and daypart based on who is expected to be watching
CTV: Bought programmatically and targeted at the household or device level
Audience data variables
Linear: Usually one or two panel-based demographics, such as age and gender
CTV: Many signals combined, including de-identified clinical, behavioral, demographic, and contextual data
Patient audience precision
Linear: Low. Most impressions reach people outside the patient population
CTV: High. Modeled patient audiences are built from real-world health data, and audience quality is measured
HCP targeting
Linear: Not possible beyond buying programming physicians might watch
CTV: Verified HCPs reached through HCP identity graphs matched to households
Reach
Linear: Large, simultaneous live reach for sports and tentpole events, but shrinking as viewers leave cable
CTV: Reaches streaming-only and cord-cutting households and extends linear campaigns with incremental audiences
Frequency control
Linear: Limited. No household-level caps across networks, so overexposure is common
CTV: Household-level caps across apps and publishers, with ACR data to deduplicate against linear exposure
In-flight optimization
Linear: Minimal. Limited to schedule changes and makegoods
CTV: Continuous, bid-level optimization toward media and pharma KPIs
Measurement & attribution
Linear: Panel ratings and GRPs. Outcome studies often arrive months after the flight
CTV: Exposure matched to de-identified claims for AQ, NBRx, TRx, and cost per verified patient, reported during the campaign
HIPAA compliance
Linear: Little targeting risk because no health data is used, but no health-based precision either
CTV: Requires de-identified, privacy-safe, HIPAA-compliant data handling, so partner choice matters
Buying model / flexibility
Linear: Upfront commitments or scatter buys, with large minimums and limited ability to cancel
CTV: Open market, private marketplace, programmatic guaranteed, or upfront deals. Budgets can shift mid-flight
Lead time / planning cycle
Linear: Long. Upfront negotiations happen months before air
CTV: Short. Campaigns can launch in days and adjust at any time
Cost structure / CPM
Linear: Lower CPM per household, but advertisers pay for every viewer, including those outside the target
CTV: Higher CPM, paid only on targeted impressions, so cost per relevant viewer is often lower
Reasons Why Healthcare Marketers are Switching to CTV Advertising
The CTV vs linear TV advertising budget shift is well underway in healthcare. eMarketer forecasts healthcare and pharma digital ad spending will reach $26.2 billion in 2026, against $6.9 billion for all traditional channels combined. CMI Media Group has called 2026 the first year pharma digital spend officially exceeds linear TV spend.
Performance data explains why. In an analysis of three pharma campaigns on the DeepIntent platform, CTV delivered up to 4X the audience quality of linear TV and converted at up to 5X the rate. DeepIntent clients see an average 48% increase in audience quality (AQ) when they run CTV inventory. Each ad also faces less clutter: linear carries about 15 minutes of ads per hour, compared with two to six minutes on streaming services, according to eMarketer. The seven reasons below show where CTV advertising effectiveness vs linear TV makes the biggest difference.
1. Reaching the Right Audiences With Precision
When planning linear TV, media buyers cast a wide net based on program demographics, no matter how small the patient population. Those decisions usually rest on one or two variables, like a show’s target age or gender. Programmatic CTV lets advertisers combine many more, from clinical and behavioral signals to demographics and context.
Machine learning makes this possible at scale. Models analyze de-identified, real-world clinical data to find correlations between demographics and disease, then build campaign-specific patient audiences with privacy-safe, HIPAA-compliant precision. The same models can find audience-specific correlations to individual shows and automatically optimize campaigns based on real-world outcomes.
Sun Pharma and its agency of record, Fingerpaint, ran a multichannel campaign with DeepIntent to raise awareness for ILUMYA®, a plaque psoriasis treatment. DeepIntent’s algorithms optimized the campaign in flight, and the brand was able to increase verified patient reach by 5.7X while decreasing cost per verified patient by 83%.
2. CTV Can Improve the Incremental Reach of Linear TV Campaigns
Linear TV still works for many pharma brands, especially for launches and live events. But a growing share of patients no longer watch it, and eMarketer analysts expect people who don’t pay for live TV to soon outnumber those who do.
Rather than framing the decision strictly as linear vs CTV, brands are using CTV to reach the audiences their linear plans miss. One lung cancer brand reached 288,000 verified patients with linear TV. Working with DeepIntent, it used CTV to reach 37,000 incremental patients, with only 4% audience overlap.
Automatic content recognition (ACR) data makes this visibility possible. ACR technology built into smart TVs logs what a household watched and when, across both live linear programming and streaming apps. Planning CTV against ACR data helps campaigns find new patients instead of re-reaching people linear already covered.
3. CTV Can Supercharge Other Digital Channels
CTV’s value extends beyond linear. For pharma advertisers focused on audience quality and script lift, CTV as a standalone channel regularly outperforms online video and display. The strongest results, though, come when channels work together.
One top pharmaceutical company invests heavily in addressable media for its largest brand, an antiviral treatment. In a multichannel campaign with DeepIntent, its agency of record found that CTV delivered 2X higher new-to-brand prescriptions (NBRx) than online video and 2.5X higher NBRx than display. Combined exposure to CTV and online video drove 4X higher NBRx than display alone, and all three channels together delivered 6X the NBRx of display.
4. Precise Frequency Management Across Campaigns
Frequency is hard to control on linear TV. Spots run across networks and dayparts with no view of how many times a household has already seen the ad, so heavy viewers get overexposed while light viewers barely see it. For pharma, that carries real risk: in a survey by iSpot and MX8 Labs, close to 57% of U.S. adults reported drug ad fatigue.
CTV lets advertisers cap frequency at the household level across apps and publishers. With ACR data, they can also suppress delivery to households already saturated on linear and shift those impressions toward under-reached audiences. DeepIntent clients have seen a 23% lift in working media by consolidating CTV with other channels for better frequency management.
5. In-Flight Optimization and Budget Control
Linear plans are typically locked months ahead through upfront negotiations, and mid-flight changes are limited to schedule swaps and makegoods. If a network or creative underperforms, the budget is usually spent before anyone knows.
CTV campaigns can be adjusted while they run. Programmatic bidding lets advertisers move spend toward the publishers, audiences, and creatives that are delivering and pull back from what isn’t, and budgets can scale up or down without renegotiating a commitment. As one CMI Media Group executive put it, “We’re expected to be optimizing almost on the fly.” DeepIntent supports that by optimizing every bid against pharma KPIs such as audience quality and script lift.
6. CTV Delivers the Attribution Linear TV Advertising Never Could
Linear TV measurement relies on panel-based ratings and gross rating points. Outcome studies, when they happen, often arrive months after the campaign ends, too late to change anything.
CTV exposure can be matched at the household level to de-identified prescription claims. That lets marketers compare exposed and unexposed households on the outcomes that matter in pharma, including audience quality, NBRx, TRx, and cost per verified patient. With reporting tied to real-world outcomes, results arrive during the campaign and feed directly into optimization. The quality of that attribution depends on the data behind it, so marketers should ask potential measurement partners hard questions about coverage and transparency.
7. Effective HCP Targeting
Linear TV offers no reliable way to reach healthcare providers. A brand can buy news programming and hope physicians are watching, but it can’t confirm who saw the ad.
On CTV, HCP identity graphs connect verified providers to their households, so brands can reach the specific prescribers they want to influence on the big screen. Kinesso put this to the test for an infectious disease brand, adding CTV to an HCP campaign that had relied on search and display. Physicians exposed to CTV were 4.5X more likely to prescribe, new patient starts rose 346%, and the campaign drove 1.9 million additional prescriptions over a year. Because CTV reaches both audiences, brands can also coordinate HCP and DTC messaging and measure outcomes across both.
Switching From Linear TV to CTV Represents the Future of Healthcare Advertising
Linear TV will keep a role in healthcare marketing, particularly for launches and live sports. But viewing has moved to streaming, and budgets are moving with it. CTV gives healthcare marketers what linear can’t: precise patient and HCP audiences, household-level frequency control, in-flight optimization, and attribution tied to prescriptions. Brands that build CTV into their plans now will be better positioned as that gap widens.
DeepIntent helps healthcare brands plan, activate, and measure CTV alongside every other channel in their media mix. Explore the DeepIntent platform to see how it can power your next campaign.
